Drug intelligence / Profile preview

DLN-9148

Development stage: Preclinical
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

DLN-9148 is a first-in-class, oral, reversible covalent inhibitor of Inducible T-cell Kinase (ITK). Developed by Delinia and later acquired by Celgene, this small molecule is designed to selectively modulate immune responses, with the primary indication being the treatment of autoimmune diseases. It was identified as Delinia's lead preclinical candidate, aimed at bolstering Celgene's immunology portfolio.

Targets

ITK (Interleukin 2-inducible T-cell kinase)

Beyond the preview

Go deeper on DLN-9148.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DLN-9148.

Explore the full profile